TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00800202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC6 iv every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg/day po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 200mg/m2 iv every 3 weeks for 6 cycles
Study: NCT01768832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tango

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Study: NCT01490879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexagon® Low Dose
Description: Twice weekly, topical application of Nexagon® low dose in addition to a Removable Cast Walker
Study: NCT02376621

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pronovum PRF-047
Description: Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pronovum PRF-047
Description: Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pronovum PRF-047
Description: Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
Study: NCT03852238

Intervention type: OTHER
Intervention: Blood test and self-administrated questionnaires
Study: NCT02985762

Intervention type: DRUG
Group type: OTHER
Intervention: EXPAREL
Study: NCT01100255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine infusion
Description: 0.5mg/kg IV over 40 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine infusion
Description: 0.5mg/kg IV over 40 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: saline infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: saline infusion
Study: NCT01490879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexagon® Medium Dose
Description: Twice weekly, topical application of Nexagon® medium dose in addition to a Removable Cast Walker
Study: NCT00180479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE V® Everolimus Eluting Coronary Stent
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.
Study: NCT04108130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Education
Description: Brochure and video about relevance of postoperative pulmonary complications, postoperative mobilization and use of incentive spirometry.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative PEEP (Positive End-Expiratory Pressure) Individualization
Description: PEEP will be set by maximizing respiratory system compliance along a decremental PEEP titration following an incremental recruitment maneuver.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualization of Neuromuscular Blockade
Description: Administration of neuromuscular blocking agents and their reversal will be done based on established protocol.
Study: NCT01490879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexagon® High Dose
Description: Twice weekly, topical application of Nexagon® high dose in addition to a Removable Cast Walker

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nexagon® vehicle
Description: Twice weekly, topical application of Nexagon® vehicle in addition to a Removable Cast Walker
Study: NCT01847781

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13
Study: NCT01085630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical observation
Study: NCT03119675

Intervention type: DEVICE
Group type: OTHER
Intervention: GoCheck Kids (iOS)
Description: Photorefraction method is used to screen amblyopia risk factors.
Study: NCT04108130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative Incentive Spirometry
Description: Participants will be encouraged to adhere to incentive spirometry to be started 2 hours after surgery and maintained until participant freely ambulates. Supervision will be provided 3 times/day for continuous education and management of barriers to optimal performance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postoperative Ambulation
Description: Participants will be encouraged to adhere to prescription of early ambulation.
Study: NCT01945905

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intramural
Description: Under this alternative, the patients will receive treatment with direct observation from health team. Treatment will be provided for free

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extramural
Description: In this form the medication will be given by a health worker in the place chosen by patients. This option will be delivered to patients with newly diagnosed pulmonary TB without hospitalization criteria
Study: NCT04445857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intrathecally
Description: coadministration of calcitonin intrathecally and a single-shot hyperbaric bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intravenously
Description: coadministration of calcitonin intravenously and a single-shot hyperbaric bupivacaine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (NS)
Description: coadministration of normal saline and a single-shot hyperbaric bupivacaine
Study: NCT02736825

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System with standard transducer
Description: Focused ultrasound energy delivered below the surface of the skin using commercially available transducer to deliver one line of treatment at a time

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System with prototype 2 simulines transducer
Description: Focused ultrasound energy delivered below the surface of the skin using new transducer to deliver two lines of treatment simultaneously
Study: NCT00650195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metolazone Tablets 10 mg
Description: 10mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zaroloxyn® Tablets 10 mg
Description: 10mg, single dose fasting
Study: NCT02380443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: AlloStim is an activated living CD4+ Th1 memory cell derived from the blood of normal blood donors and intentionally mismatched to the recipient. AlloStim is bioengineered to express high levels of Type 1 inflammatory cytokines (such as interferon-gamma, TNF-alpha, GM-CSF) and immunomodulatory molecules such as CD40L. AlloStim has CD3/CD28-coated microbeads attached to assure activation upon infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: AlloStim is an activated living CD4+ Th1 memory cell derived from the blood of normal blood donors and intentionally mismatched to the recipient. AlloStim is bioengineered to express high levels of Type 1 inflammatory cytokines (such as interferon-gamma, TNF-alpha, GM-CSF) and immunomodulatory molecules such as CD40L. AlloStim has CD3/CD28-coated microbeads attached to assure activation upon infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: AlloStim is an activated living CD4+ Th1 memory cell derived from the blood of normal blood donors and intentionally mismatched to the recipient. AlloStim is bioengineered to express high levels of Type 1 inflammatory cytokines (such as interferon-gamma, TNF-alpha, GM-CSF) and immunomodulatory molecules such as CD40L. AlloStim has CD3/CD28-coated microbeads attached to assure activation upon infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: AlloStim is an activated living CD4+ Th1 memory cell derived from the blood of normal blood donors and intentionally mismatched to the recipient. AlloStim is bioengineered to express high levels of Type 1 inflammatory cytokines (such as interferon-gamma, TNF-alpha, GM-CSF) and immunomodulatory molecules such as CD40L. AlloStim has CD3/CD28-coated microbeads attached to assure activation upon infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Percutaneous partial cryoablation of a single metastatic tumor lesion in the liver. The procedure is conducted under CT or ultrasound image-guidance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Percutaneous partial cryoablation of a single metastatic tumor lesion in the liver. The procedure is conducted under CT or ultrasound image-guidance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Percutaneous partial cryoablation of a single metastatic tumor lesion in the liver. The procedure is conducted under CT or ultrasound image-guidance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Percutaneous partial cryoablation of a single metastatic tumor lesion in the liver. The procedure is conducted under CT or ultrasound image-guidance
Study: NCT00813852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training, IMT
Description: Each exercise session includes graded treadmill walking and resisted exercises. The graded treadmill walking exercise begins with a 5 minute warm-up period with the intensity of about 40% of maximal oxygen consumption (VO2max) follows by a 30 minutes training phase. The training intensity is set at about 70%-85% of VO2max and ends with a 5-minute cool-down period with the intensity of about 40% of VO2max. The resisted exercise program includes 20 minutes of weight training with rest after the first 5 minutes.
Study: NCT00985725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 (Lisdexamfetamine dimesylate)
Description: Oral, 20, 30, 40, 50, 60, and 70mg capsules, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: oral, once daily
Study: NCT03517592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMDR
Description: The EMDR SUD Protocol consists of a detailed interview with respect to traumatic events, the treatment of those with the EMDR standard protocol and a further specific protocol for SUD that is focused on the concept of addiction memory.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: The TAU condition includes follow-up visits with the psychiatry, psychology and with the nursing service. Visits with the psychiatrist consist to evaluate clinical status and readjust the pharmacological treatment if necessary while visits with the psychologist consist to assess and detect risk situations and to prevent relapses using a cognitive behavioral approach. Finally, the nursing service will provide health and care habits and will carry out the abstinence controls.
Study: NCT01548430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP4000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP4000

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01925625

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Early CDT Lung blood test
Description: The EarlyCDT-Lung Test is an early detection test designed to assist in lung cancer risk assessment and detection in the earliest stages of the disease.
Study: NCT03756584

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theta-burst stimulation
Description: iTBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz) as described previously (Huang, Edwards et al. 2005) and consists of 2-second trains with an inter-train-interval of 8 seconds. We will repeat trains (30 pulses; 10 bursts) for 20 times to reach a total number of 600 pulses per session (3x10x20)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-burst stimulation
Description: iTBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz) as described previously (Huang, Edwards et al. 2005) and consists of 2-second trains with an inter-train-interval of 8 seconds. We will repeat trains (30 pulses; 10 bursts) for 20 times to reach a total number of 600 pulses per session (3x10x20)
Study: NCT04536259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Default
Description: The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation by video.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend a video consultation. B) If possible, I would rather attend the appointment in person.
Study: NCT00105235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: T-cell depleting monoclonal antibody; two doses by intravenous infusion on Days 0 and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Oral immunosuppressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Oral immunosuppressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral immunosuppressant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplant
Description: Occurs at study entry

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immunosuppression withdrawal
Description: Beginning no earlier than Year 1
Study: NCT00530803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA Cream
Description: 60 minutes x1

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Synera Patch
Description: 20 minutes x1
Study: NCT02405260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP399 400 mg
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP399 800 mg
Description: once daily
Study: NCT04536259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person Default
Description: The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend an in-person consultation. B) If possible, I would rather attend the appointment by video.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Choice
Description: The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend a consultation by video or in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) I would prefer a video consultation. B) I would prefer an in-person consultation.
Study: NCT04168476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interscapular muscle release or scapular mobilization technique as described by Travell and Simons.
Description: Patient is sidelying with the testing side up. The auditor stands in front of the patient, reaches over the patient's shoulder to grasp the upper portion of the vertebral border of the scapula, and the other arm reaches under the patient's humerus to grasp the lower portion of the vertebral border of the scapula.~The auditor then slowly moves the scapula into elevation/depression, internal/external rotation/abduction and adduction.~To standardize the technique and be able to reproduce it in each participant, a set of 10 repetitions for each movement was performed in the same order.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Calcaneus abduction and adduction mobilization technique
Description: Abduction and adduction mobilization of the calcaneus is carried out in the opposite side of the upper extremity measured.
Study: NCT00778947

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Harmonic Synergy Dissecting Hook (Harmonic Scalpel)
Description: Harmonic Synergy Dissecting Hook (Harmonic Scalpel) uses ultrasound waves to coagulate and cut in surgery. It is available on the market, holds a CE mark and is coded as a Class IIb medical device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery Diathermy
Description: Electrosurgery uses high temperatures (150-400oC) and causes obliterative coagulation. Diathermy is the use of high frequency electric current to produce heat. In surgery it is used to cut or destroy tissue and/or to produce coagulation. The electrical frequency produced in diathermy is in the range of 300kHz to 3MHz.
Study: NCT00194103

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Monitoring and Feedback
Description: In addition to attending IOP, participants receive phone contact from our counselors but only to receive a monitoring assessment. There is no feedback or counseling from study staff in this condition.
Study: NCT02405260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100 mg
Description: once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study: NCT04009590

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Read educational booklet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Utilize Quit4Health
Study: NCT04035824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gastrodia and Uncaria granule
Description: Patients allocated to the intervention group take 10g of Gastrodia and Uncaria granule each time, twice per day, and for two months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Gastrodia and Uncaria granule
Description: Patients allocated to the control group take 10g of placebo of Gastrodia and Uncaria granule each time, twice per day, and for two months. The placebo has similar appearance and smell to genuine drug but has no effective anti-hypertensive agents.
Study: NCT00194103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Monitoring and Counseling
Description: In addition to attending IOP, participants have phone contact with study counselors, which includes monitoring, feedback, and counseling.
Study: NCT01440530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
Study: NCT00186927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sendai virus vaccine
Description: Enders strain; a live, unmodified intranasally administered Sendai virus vaccine; given once in a dose escalation study, 5 x 10\^5 to 5 x 10\^7 EID(50) units.
Study: NCT03558100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obstacle crossing intervention for adults with obesity
Description: The obstacle crossing intervention will be done for reducing falls risks in obesity. The intervention will provide gait practice to individuals with obesity who are eligible for and prior to weight loss surgery.
Study: NCT01784133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omiganan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omiganan
Study: NCT03119675

Intervention type: DEVICE
Group type: OTHER
Intervention: GoCheck Kids (Windows)
Description: Photorefraction method is used to screen amblyopia risk factors.
Study: NCT04500964

Intervention type: DEVICE
Intervention: TAVR
Description: Trancatheter aortic valve replacement

Intervention type: DEVICE
Intervention: TAVR
Description: Trancatheter aortic valve replacement

Intervention type: DEVICE
Intervention: TAVR
Description: Trancatheter aortic valve replacement
Study: NCT00986128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 100 mg tablet twice daily for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: One 100 mg and one 200 mg tablet twice daily for 3 weeks
Study: NCT05262309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Description: Pamrevlumab dosing, 30 mg/kg IV, will be administered at day 1, day 7 and day 14.~Based on Investigator's decision, treatment may be continued every 3 weeks after day 14, up to 11 weeks.